Department of Orthopedic Surgery, The Warren Alpert School of Medicine at Brown University, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA.
Expert Rev Med Devices. 2012 Mar;9(2):111-22. doi: 10.1586/erd.11.76.
Autogenous bone graft (autograft) is currently the gold standard for augmenting bone repair and fusion procedures of the foot and ankle. The time, cost and morbidity involved in obtaining autograft, however, are well documented and legitimate concerns remain surrounding this intervention. Endogenous human PDGF is chemotactic and mitogenic for osteoblasts and undifferentiated osteoprogenitor cells, and upregulates expression of cytokines necessary for osseous and soft tissue healing and regeneration. The BB isoform of PDGF, and the biosynthetic replica recombinant human PDGF-BB, is a key regulatory molecule in bone homeostasis, repair and regeneration. When combined with a β-tricalcium phosphate osteoconductive matrix, recombinant human PDGF-BB mitigates a number of problems associated with the use of autograft and, based on its preclinical performance and early clinical success, appears to be an equally effective and perhaps an even safer alternative to autograft for foot and ankle fusion (arthrodesis) procedures.
自体骨移植（自体移植物）目前是增强足部和踝关节骨修复和融合手术的金标准。然而，获得自体移植物所涉及的时间、成本和发病率是有据可查的，人们对这种干预措施仍然存在合理的担忧。内源性人 PDGF 对成骨细胞和未分化的成骨前体细胞具有趋化性和有丝分裂原作用，并上调骨和软组织愈合和再生所需细胞因子的表达。PDGF 的 BB 同工型和合成的复制重组人 PDGF-BB 是骨内稳态、修复和再生的关键调节分子。当与β-磷酸三钙骨传导基质结合时，重组人 PDGF-BB 减轻了与使用自体移植物相关的许多问题，并且基于其临床前性能和早期临床成功，对于足部和踝关节融合（关节融合）手术而言，它似乎是与自体移植物同样有效甚至更安全的替代物。
